Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
Cancer Discov
; 11(2): 233-236, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-1140381
ABSTRACT
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Health Care Rationing
/
Hematologic Neoplasms
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Cancer Discov
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS